Literature DB >> 23345816

Reassessing models of hepatic extraction.

D Ridgway1, J A Tuszynski, Y K Tam.   

Abstract

The aim of this investigation is to compare different mathematical models of the liver in the context of in vitro-in vivo correlation. We reanalyze drugs from the Houston reviews [1, 2], and compare the mathematical models. For the well-stirred model, a particular form of the distributed tubes model, and the dispersion model, fits are done to in vitro and in vivo intrinsic clearance data from microsomal and hepatocyte experiments. The distributed and dispersion models have decreased residuals as compared to the well-stirred model, but neither is to be clearly preferred over theother. It seems likely that drug-specific factors have a major impact on the quality of IVIVC correlations. While new experiments are needed to validate IVIVC models, our results indicate that improved correlation of in vitroand in vivo data is possible for high clearance drugs by using either a dispersion or distributed tube model rather than a well-stirred model.

Entities:  

Keywords:  in vivo-in vitro correlations; multi-compartment models; pharmacokinetics

Year:  2003        PMID: 23345816      PMCID: PMC3456842          DOI: 10.1023/A:1022531403741

Source DB:  PubMed          Journal:  J Biol Phys        ISSN: 0092-0606            Impact factor:   1.365


  32 in total

1.  Interconnected-tubes model of hepatic elimination: steady-state considerations.

Authors:  Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Theor Biol       Date:  1999-08-21       Impact factor: 2.691

Review 2.  Noncompartmental versus compartmental modelling in clinical pharmacokinetics.

Authors:  W R Gillespie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  Pitfalls in pharmacokinetic multicompartment analysis.

Authors:  E Liang; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

4.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1997-12       Impact factor: 3.922

Review 5.  Controversy III: To model or not to model.

Authors: 
Journal:  J Clin Pharmacol       Date:  1988-10       Impact factor: 3.126

6.  Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats.

Authors:  M Chiba; S Fujita; T Suzuki
Journal:  J Pharm Sci       Date:  1990-04       Impact factor: 3.534

7.  A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations.

Authors:  M S Roberts; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1986-06

8.  Use of unbound drug concentration in blood to discriminate between two models of hepatic drug elimination.

Authors:  D J Morgan; K Raymond
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

9.  In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.

Authors:  D J Carlile; A J Stevens; E I Ashforth; D Waghela; J B Houston
Journal:  Drug Metab Dispos       Date:  1998-03       Impact factor: 3.922

Review 10.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10
View more
  6 in total

Review 1.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

2.  Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research.

Authors:  Marianthi G Lerapetritou; Panos G Georgopoulos; Charles M Roth; Loannis P Androulakis
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

3.  Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Authors:  Shufan Ge; Yifan Tu; Ming Hu
Journal:  Curr Pharmacol Rep       Date:  2016-11-08

4.  Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.

Authors:  Elisa A M Calvier; Thu Thuy Nguyen; Trevor N Johnson; Amin Rostami-Hodjegan; Dick Tibboel; Elke H J Krekels; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2018-09-14       Impact factor: 4.200

5.  Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method.

Authors:  E A M Calvier; E H J Krekels; T N Johnson; A Rostami-Hodjegan; D Tibboel; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2019-03-08       Impact factor: 4.009

6.  Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Authors:  Elisa A M Calvier; Elke H J Krekels; Pyry A J Välitalo; Amin Rostami-Hodjegan; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.